MMSI Earnings Reaction: Street Lifts Targets, Stock Still Down 8%

Merit Medical Systems delivered its Q3 results on October 29 and the market's verdict was swift: the stock fell 6.5% on the day and extended losses to close the week down 7.6% at $86.24, even as analysts responded by raising price targets across the board.

The post-earnings analyst reaction is the most interesting tension here. Four firms moved their targets higher within 24 hours of the print. JP Morgan's Robbie Marcus lifted his target from $95 to $110, keeping his Overweight rating. Needham raised to $106 from $101, and BTIG moved to $110 from $105, both maintaining Buy. Wells Fargo nudged to $92 from $83 while holding Equal-Weight. Freedom Capital Markets added a fresh Hold initiation at $90 on October 27, just before the print. The consensus mean target now sits at $100.67, implying around 17% upside to the current price. That gap between where analysts think the stock should be and where it is trading is the story this week.

Positioning going into earnings told the same cautious story that earlier notes flagged, and the data since the print has shifted only modestly. Short interest reached 6.7% of free float on October 29, up 4.5% on the week and 16% over the past month. That build was the most concentrated bearish position ORTEX had recorded for MMSI in its data window, and the shorts were in place before the stock dropped. The borrow market remains completely unstressed: availability is extremely loose at 1,580%, meaning roughly sixteen shares are available to lend for every one already borrowed, and borrowing costs ticked down to 0.42%, the lowest level in the 30-day window. That lending setup separates the short position from any squeeze dynamic. The put/call ratio has eased slightly to 0.82 from the 0.84 peak seen on October 29, but it remains well above its 20-day average of 0.61, still about 1.2 standard deviations elevated. Options traders have not fully unwound their defensive positioning despite the sell-off already occurring.

The bull and bear debate now centres on whether the Q3 reaction was an overreaction to execution noise or confirmation of a structural problem. The bull case points to a credible medium-term plan: management targeting a 6.6% organic revenue CAGR through 2026, operating margins expanding toward 21.2%, and cumulative free cash flow of $634 million against a $400 million target, with the mix shifting toward faster-growing Therapeutic Products. The bear case is more pointed: revenue growth at or below 5% tied to weak acquisition contributions and failed product launches would pressure margins and leave earnings below consensus. The current trailing P/E is around 20x and EV/EBITDA 13.2x, neither extreme, but both have drifted higher over the past 30 days as earnings fell faster than multiples compressed. The EPS surprise factor score ranks in only the 36th percentile, meaning Merit has not been consistently beating estimates, and the short score of 47 has crept up steadily from 45 at mid-month.

Peer context adds nuance. GEHC gained 7.2% over the same week MMSI fell 7.6%, the sharpest divergence in the peer group. SYK dropped 5% and BAX fell 9%, so the med-tech space had a mixed week. MMSI's decline is therefore partly sector, partly stock-specific. The Q3 reaction in isolation is worth noting: the single earnings move recorded in ORTEX's history shows a 6.5% next-day decline, which is effectively this week's event. The next print is not until February 24, 2027, giving 116 days for the analyst upgrades and the stock price to either converge or diverge further.

Wikipedia attention spiked sharply in the week of October 19, with an attention z-score of 6.7 against MMSI's own 90-day history, a sign of elevated retail interest that tracked the earnings week. That is colour rather than a leading indicator: no alt data datasets have been measured to lead MMSI's reported figures.

What to watch next: whether the post-earnings short interest, which built throughout October, begins to unwind now that the catalyst has passed, and whether any of the analysts who raised targets after the print attract institutional follow-through at current levels.